Trevi Therapeutics, Inc.
TRVI
$14.76
-$0.12-0.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.08% | 30.47% | 26.53% | 19.67% | 17.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.29% | -4.26% | 6.50% | 19.34% | 33.51% |
| Operating Income | -3.29% | 4.26% | -6.50% | -19.34% | -33.51% |
| Income Before Tax | 3.59% | 10.68% | -3.48% | -22.07% | -41.03% |
| Income Tax Expenses | -111.76% | -103.23% | -6.90% | -327.27% | -3.03% |
| Earnings from Continuing Operations | 3.67% | 10.75% | -3.48% | -21.99% | -41.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.67% | 10.75% | -3.48% | -21.99% | -41.06% |
| EBIT | -3.29% | 4.26% | -6.50% | -19.34% | -33.51% |
| EBITDA | -3.32% | 4.27% | -6.51% | -19.39% | -33.61% |
| EPS Basic | 27.87% | 31.76% | 15.80% | -8.48% | -32.69% |
| Normalized Basic EPS | 27.83% | 31.72% | 15.84% | -8.54% | -32.73% |
| EPS Diluted | 27.87% | 31.76% | 15.80% | -8.48% | -32.69% |
| Normalized Diluted EPS | 27.83% | 31.72% | 15.84% | -8.54% | -32.73% |
| Average Basic Shares Outstanding | 33.01% | 32.05% | 24.36% | 13.99% | 7.28% |
| Average Diluted Shares Outstanding | 33.01% | 32.05% | 24.36% | 13.99% | 7.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |